CHICAGO--The showdown between Bristol-Myers Squibb ($BMY) and Merck ($MRK) over a new PD-1 approach to spurring an immune response to cancer didn't disappoint.
A technique known as metabolomics may enable an Alzheimer's disease blood test diagnosis before patients start displaying symptoms, Mayo Clinic scientists have concluded.
QPS is reaching out to Hepregen to boost its early stage development offerings, licensing the company's "liver-in-a-dish" technology for drug metabolism and pharmacokinetic testing.
Roche took two steps forward and one step back on the Avastin front today, as investigators laid out a clear advantage in adding the therapy to chemo for cervical cancer while finding no survival advantage when adding it to first-line treatment of an aggressive form of brain cancer.
Merck's team arrived at ASCO with some solid positive data backing their melanoma program for lambrolizumab (MK-3475). The pharma giant is readying a pair of late-stage clinical trials for melanoma and non-small cell lung cancer as they set their sights on completing a speedy set of applications for regulators.
Bayer and Onyx appear poised to expand sales of Nexavar (sorafenib). Investigators told the crowd at ASCO Sunday morning that their therapy almost doubled progression-free survival of treatment-resistant thyroid cancer patients, from a median 5.8 months in the control arm to 10.8 months in the treatment group.
Bristol-Myers Squibb arrived at ASCO with one of the most closely watched experimental immunotherapy drugs in the pipeline. And racing against some major league rivals, the biopharma company will leave with its frontrunner reputation for nivolumab intact.
The FDA's oncology chief, Richard Pazdur, used his turn in front of the press mob at ASCO today to make some very public vows about his commitment to the newly launched breakthrough-drug program, that intriguing new classification for certain stellar therapeutic programs that will be extended VIP status at the agency.
The industry is abuzz about the breakthrough potential of new immunotherapies to restore immune attacks on cancers
Even before the ASCO meeting opened today, the industry has been abuzz about the breakthrough potential of new immunotherapies to restore immune attacks on cancers.